(Q37744764)

22 August 2017

1 reference

title

Improving induction therapy in multiple myeloma (English)

1 reference

22 August 2017

3

Sagar Lonial

1 reference

22 August 2017

Ajay Nooka

1

1 reference

22 August 2017

Charise Gleason

series ordinal

2

1 reference

22 August 2017

publication date

1 July 2010

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

119-128

1 reference

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

22 August 2017

cites work

1 reference

12 December 2020

Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation

1 reference

12 December 2020

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

12 December 2020

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

12 December 2020

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

1 reference

12 December 2020

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

12 December 2020

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

12 December 2020

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

12 December 2020

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

1 reference

12 December 2020

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates

1 reference

12 December 2020

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

12 December 2020

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

12 December 2020

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

12 December 2020

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results

1 reference

12 December 2020

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

1 reference

12 December 2020

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

12 December 2020

10.1007/S11899-010-0057-7

Identifiers

DOI

1 reference

22 August 2017

1 reference